GO:0004334 fumarylacetoacetase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004334 fumarylacetoacetase activity is a molecular_function defined as catalysis of the reaction 4-fumarylacetoacetate + H2O = acetoacetate + fumarate + H+.
• The enzyme is best known as fumarylacetoacetate hydrolase (FAH), the final step of tyrosine catabolism, and its deficiency causes hereditary tyrosinemia type I.
• Assays of fumarylacetoacetase activity in cultured and non-cultured chorionic villus cells enable prenatal diagnosis and carrier detection.
• Low fumarylacetoacetase activity leads to accumulation of succinylacetone, a diagnostic marker measured after tyrosine or homogentisate loading.
• Some patients show self-induced correction of the FAH defect, a phenomenon relevant to gene-editing and cell-model research.
• CRISPR knockout, point-mutation, knock-in and overexpression models are powerful tools to dissect FAH function and tyrosinemia biology.
Description
GO:0004334 fumarylacetoacetase activity is a molecular_function term describing the catalysis of the reaction 4-fumarylacetoacetate + H2O = acetoacetate + fumarate + H+. This activity is the final enzymatic step in the tyrosine degradation pathway and is essential for normal amino acid metabolism. Researchers study this term because loss of fumarylacetoacetase activity causes hereditary tyrosinemia type I, a severe metabolic disease with liver and kidney involvement. The enzyme is also a key marker for prenatal diagnosis and carrier detection, and its activity can be measured in chorionic villus cells and other tissues. In addition, low fumarylacetoacetase activity is associated with elevated succinylacetone concentrations, which are used clinically to monitor patients. Understanding this activity at the molecular level informs the development of CRISPR-based cell models and therapeutic strategies.
fumarylacetoacetase activity At A Glance
| GO ID | GO:0004334 |
|---|---|
| GO term | fumarylacetoacetase activity |
| Ontology | molecular_function |
| Synonym | 4-fumarylacetoacetate fumarylhydrolase activity; beta-diketonase activity; fumarylacetoacetate hydrolase activity |
| Definition | Catalysis of the reaction: 4-fumarylacetoacetate + H2O = acetoacetate + fumarate + H+ |
| Major function | Final step of tyrosine catabolism; hydrolyzes fumarylacetoacetate |
| Associated disease | Hereditary tyrosinemia type I |
| Diagnostic relevance | Enzyme activity assay for prenatal diagnosis and carrier detection |
| Key metabolite | Succinylacetone accumulates when activity is low |
What Is GO:0004334?
Fumarylacetoacetase activity (GO:0004334) is the catalytic function of an enzyme that hydrolyzes 4-fumarylacetoacetate into acetoacetate, fumarate and a proton. This reaction is the last step of tyrosine catabolism, and the enzyme is commonly known as fumarylacetoacetate hydrolase (FAH). The activity is measured in vitro by detecting the formation of acetoacetate or fumarate, or by using coupled assays. Deficiencies in this activity are linked to metabolic disorders such as tyrosinemia type I.
Why Is fumarylacetoacetase activity Important in Cell Biology?
Fumarylacetoacetase activity is critical because it completes the tyrosine degradation pathway, and its deficiency causes hereditary tyrosinemia type I, a disease characterized by liver failure, renal dysfunction and increased risk of hepatocellular carcinoma. Measuring this activity is essential for prenatal diagnosis and carrier identification, as demonstrated in chorionic villus cell assays. Moreover, the accumulation of succinylacetone, a toxic metabolite, is directly linked to low fumarylacetoacetase activity and is used as a biomarker. Research on this activity also provides insights into self-induced correction mechanisms, which may inform gene-editing therapies.
• Deficiency causes hereditary tyrosinemia type I, a severe metabolic disorder.
• Enzyme activity assays are used for prenatal diagnosis and carrier detection.
• Low activity leads to succinylacetone accumulation, a diagnostic marker.
• The enzyme is the final step in tyrosine catabolism, essential for metabolic homeostasis.
• Self-induced correction of the defect has been observed, offering clues for therapeutic intervention.
• Fumarylacetoacetase activity is a target for CRISPR-based disease modeling.
• Assays in chorionic villus cells enable early diagnosis.
• The activity is relevant to liver stem cell research and hepatocyte expansion.
• Understanding the enzyme supports development of small-molecule or gene therapies.
• It serves as a model for studying metabolic enzyme deficiencies and genotype-phenotype correlations.
Molecular Mechanism of fumarylacetoacetase activity
Substrate binding and catalysis
In simple terms: The enzyme grabs a molecule called 4-fumarylacetoacetate and breaks it apart using water.
Fumarylacetoacetase binds its substrate, 4-fumarylacetoacetate, and catalyzes a hydrolytic cleavage that yields acetoacetate, fumarate and a proton. This reaction is the final step of tyrosine catabolism. The enzyme is also known as fumarylacetoacetate hydrolase (FAH) and belongs to the hydrolase family. The catalytic mechanism involves water-mediated cleavage of the carbon-carbon bond, although detailed structural studies are ongoing.
Role in tyrosine catabolism
In simple terms: This enzyme is the last worker on the tyrosine breakdown assembly line.
In the tyrosine degradation pathway, fumarylacetoacetase acts after several upstream enzymes to convert 4-fumarylacetoacetate into acetoacetate and fumarate. These products can enter other metabolic pathways, such as the citric acid cycle or ketone body metabolism. When the enzyme is deficient, upstream metabolites like succinylacetone accumulate, leading to toxicity.
Enzyme deficiency and metabolic consequences
In simple terms: If this enzyme is missing, harmful substances build up and damage the liver and kidneys.
Loss of fumarylacetoacetase activity results in hereditary tyrosinemia type I, characterized by accumulation of succinylacetone and other toxic metabolites. Succinylacetone inhibits porphyrin synthesis and is used as a diagnostic marker. Patients may present with liver failure, renal Fanconi syndrome, and increased risk of hepatocellular carcinoma. Some patients exhibit self-induced correction of the enzyme defect, where a subset of hepatocytes reverts to normal function.
Assays for measuring activity
In simple terms: Doctors and scientists can measure how well this enzyme works using tissue samples.
Fumarylacetoacetase activity can be assayed in cultured and non-cultured chorionic villus cells, as well as in other tissues. These assays are used for prenatal diagnosis and carrier detection in families at risk for tyrosinemia type I. Typically, the assay measures the formation of acetoacetate or fumarate spectrophotometrically or via coupled enzymatic reactions. Low activity confirms the diagnosis.
Regulation of enzyme levels
In simple terms: The amount of this enzyme in cells can change based on genetic and environmental factors.
The expression of FAH is primarily regulated at the transcriptional level, but post-translational modifications may also play a role. In tyrosinemia type I, mutations in the FAH gene lead to reduced enzyme activity. Additionally, self-induced correction mechanisms can restore activity in some hepatocytes, possibly through genetic reversion or selective advantage. Research on hepatocyte expansion and reprogramming may provide further insights into regulation.
Key Genes Involved in GO:0004334 fumarylacetoacetase activity
The following genes and proteins are directly or indirectly associated with fumarylacetoacetase activity and its metabolic pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FAH | Encodes fumarylacetoacetate hydrolase, the enzyme with GO:0004334 activity | Primary gene for tyrosinemia type I; target for knockout and knock-in models |
| HPD | 4-hydroxyphenylpyruvate dioxygenase, upstream in tyrosine catabolism | Mutations cause tyrosinemia type III; relevant for pathway studies |
| HGD | Homogentisate 1,2-dioxygenase, upstream enzyme | Deficiency causes alkaptonuria; used in metabolic models |
| TAT | Tyrosine aminotransferase, first step of tyrosine catabolism | Regulates tyrosine levels; potential modifier |
| GSTZ1 | Maleylacetoacetate isomerase, upstream of FAH | Deficiency leads to accumulation of maleylacetoacetate |
| LGR5 | Liver stem cell marker | Used for in vitro expansion of liver stem cells |
| IL22 | Interleukin-22, supports hepatocyte expansion | Used for long-term hepatocyte culture |
| FOXA3 | Transcription factor for hepatocyte reprogramming | Direct reprogramming of fibroblasts to hepatocytes |
| HNF1A | Hepatocyte nuclear factor 1 alpha | Reprogramming factor for hepatocyte-like cells |
| HNF4A | Hepatocyte nuclear factor 4 alpha | Reprogramming factor for hepatocyte-like cells |
| G6PC | Glucose-6-phosphatase, hepatocyte marker | Assesses hepatocyte function in models |
| ALB | Albumin, hepatocyte marker | Confirms hepatocyte identity in reprogrammed cells |
| CYP3A4 | Cytochrome P450, hepatocyte marker | Functional marker for hepatocyte-like cells |
| ASGR1 | Asialoglycoprotein receptor 1, hepatocyte marker | Used for sorting hepatocyte-like cells |
| AFP | Alpha-fetoprotein, fetal hepatocyte marker | Marker for immature hepatocytes |
| KRT19 | Keratin 19, cholangiocyte marker | Distinguishes cholangiocytes from hepatocytes |
| TP53 | Tumor suppressor, often mutated in hepatocellular carcinoma | Relevant for cancer studies in tyrosinemia models |
| CTNNB1 | Beta-catenin, involved in liver regeneration | Wnt-driven regeneration in liver stem cells |
How Is fumarylacetoacetase activity Regulated?
Fumarylacetoacetase activity is primarily regulated by the expression level of the FAH gene, and mutations in FAH lead to reduced activity in tyrosinemia type I. In some patients, self-induced correction of the enzyme defect occurs, possibly through genetic reversion or selective proliferation of corrected hepatocytes. Additionally, the activity can be influenced by substrate availability and upstream metabolites in the tyrosine catabolism pathway. Research on hepatocyte expansion and reprogramming suggests that cellular context and transcription factors such as FOXA3, HNF1A and HNF4A can affect the expression of metabolic enzymes including FAH. However, direct regulatory mechanisms beyond genetic mutations are not fully characterized.
fumarylacetoacetase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FAH | Hereditary tyrosinemia type I | FAH knockout hepatocytes or iPSC-derived hepatocytes; point-mutation knock-in |
| FAH | Hepatocellular carcinoma | FAH knockout mouse models or liver organoids; CRISPR screens |
| FAH | Carrier state and prenatal diagnosis | Chorionic villus cell assays; enzyme activity measurement |
| HPD | Tyrosinemia type III | HPD knockout cell models; metabolic profiling |
| HGD | Alkaptonuria | HGD knockout models; pigmentation studies |
Hereditary tyrosinemia type I
Hereditary tyrosinemia type I is an autosomal recessive disorder caused by deficiency of fumarylacetoacetase activity due to mutations in the FAH gene. Patients accumulate toxic metabolites such as succinylacetone, leading to liver failure, renal Fanconi syndrome, and hepatocellular carcinoma. Diagnosis is confirmed by measuring fumarylacetoacetase activity in tissues or by detecting succinylacetone in blood or urine. Prenatal diagnosis is possible through enzyme assay in chorionic villus cells.
Liver cancer and hepatocellular carcinoma
Chronic tyrosinemia type I is associated with a high risk of hepatocellular carcinoma, likely due to the carcinogenic effects of accumulated metabolites like succinylacetone. The self-induced correction of the enzyme defect in some hepatocytes may create a selective advantage, but remaining deficient cells can undergo malignant transformation. Research using hepatocyte models and CRISPR knockouts can help dissect the mechanisms linking FAH deficiency to cancer.
Carrier detection and prenatal diagnosis
Assays for fumarylacetoacetase activity are used to detect carriers of tyrosinemia type I and for prenatal diagnosis in high-risk pregnancies. Low enzyme activity in chorionic villus cells or cultured amniocytes indicates an affected fetus. These assays are critical for genetic counseling and early intervention.
From fumarylacetoacetase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of FAH loss on tyrosine catabolism? | FAH knockout cell lines (e.g., HepG2, iPSC-derived hepatocytes) |
| How do specific FAH mutations affect enzyme activity? | Point-mutation knock-in models (e.g., c.1062+5G>A, c.554-1G>T) |
| Can corrected FAH restore metabolic function? | Knock-in of wild-type FAH or tagged FAH for localization |
| Does FAH overexpression protect against metabolite toxicity? | FAH overexpression in hepatocyte cell lines |
| What genes cooperate with FAH in tyrosinemia? | CRISPR library screening in FAH-knockout background |
| How does FAH deficiency affect liver stem cell expansion? | LGR5+ liver stem cell organoids with FAH knockout |
How to Study the fumarylacetoacetase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Catalytic conversion of 4-fumarylacetoacetate to acetoacetate and fumarate | Diagnosis of tyrosinemia type I; carrier detection |
| Succinylacetone quantification | Accumulation of toxic metabolite | Monitoring disease and treatment response |
| DNA sequencing | Mutations in FAH gene | Genetic confirmation and prenatal diagnosis |
| CRISPR knockout | Loss of FAH function | Modeling tyrosinemia and studying metabolic pathways |
| CRISPR knock-in | Introduction of specific FAH mutations | Genotype-phenotype correlation |
| Overexpression | Increased FAH levels | Rescue experiments and functional studies |
| Liver organoid culture | Hepatocyte function and expansion | Disease modeling and drug screening |
| Metabolomics | Global metabolic changes | Pathway analysis and biomarker discovery |
Enzyme activity assays
Fumarylacetoacetase activity is measured using spectrophotometric or coupled enzymatic assays that detect the formation of acetoacetate or fumarate. These assays are performed on tissue homogenates, cultured cells, or chorionic villus samples. They are essential for diagnosing tyrosinemia type I and for carrier detection.
Metabolite profiling
Quantification of succinylacetone and other metabolites by mass spectrometry or HPLC is used to assess fumarylacetoacetase activity in vivo. Succinylacetone is a sensitive and specific marker for tyrosinemia type I. Loading tests with tyrosine or homogentisate can reveal low enzyme activity.
Genetic and genomic methods
Mutation analysis of the FAH gene by Sanger sequencing or next-generation sequencing confirms the genetic basis of enzyme deficiency. CRISPR-based knockout and knock-in models allow functional studies of specific mutations. Transcriptomic profiling can reveal downstream effects of FAH loss.
Cell and organoid models
Primary hepatocytes, iPSC-derived hepatocytes, and liver organoids are used to study fumarylacetoacetase activity in a physiologically relevant context. These models enable investigation of self-induced correction and drug responses. Hepatocyte reprogramming from fibroblasts provides an additional tool.
How CRISPR Can Be Used to Study GO:0004334 fumarylacetoacetase activity
Knockout
CRISPR knockout of FAH in hepatocyte cell lines or iPSCs abolishes fumarylacetoacetase activity, leading to accumulation of succinylacetone and other metabolites. These models mimic tyrosinemia type I and are used to study disease mechanisms and test therapeutic interventions.
Point Mutation
Introducing specific FAH mutations (e.g., c.1062+5G>A, c.554-1G>T) via CRISPR point-mutation knock-in allows researchers to study the impact of individual mutations on enzyme activity and disease severity. These models help correlate genotype with phenotype.
Knock-in
Knock-in of wild-type FAH or tagged FAH (e.g., GFP-FAH) enables visualization of enzyme localization and restoration of activity in deficient cells. This approach is useful for studying self-induced correction and for developing gene therapies.
Overexpression
Overexpression of FAH in cell lines or hepatocytes can protect against metabolite toxicity and provide insights into the enzyme's role in metabolic homeostasis. It is also used to study the effects of increased enzyme activity on tyrosine catabolism.
How EDITGENE Supports fumarylacetoacetase activity Research
Researchers studying fumarylacetoacetase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic pathways, disease progression, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to create precise cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for fumarylacetoacetase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| FAH Knockout A-549 Cell Line | EDJ-KQ42832 | Human | 2184 | Details Get a Quote |
| FAH Knockout HCT 116 Cell Line | EDJ-KQ42833 | Human | 2184 | Details Get a Quote |
| FAH Knockout HeLa Cell Line | EDJ-KQ42834 | Human | 2184 | Details Get a Quote |
| FAH Knockout Hep-G2 Cell Line | EDJ-KZ233 | Human | 2184 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
Frequently Asked Questions About fumarylacetoacetase activity
What is fumarylacetoacetase activity?
Fumarylacetoacetase activity (GO:0004334) is the catalytic function of an enzyme that hydrolyzes 4-fumarylacetoacetate into acetoacetate, fumarate and a proton, the final step of tyrosine catabolism.
What genes are involved in fumarylacetoacetase activity?
The primary gene is FAH, which encodes fumarylacetoacetate hydrolase. Other genes in the tyrosine catabolism pathway include HPD, HGD, TAT and GSTZ1.
What diseases are associated with low fumarylacetoacetase activity?
Low activity causes hereditary tyrosinemia type I, characterized by liver failure, renal dysfunction and increased risk of hepatocellular carcinoma.
How is fumarylacetoacetase activity measured?
It is measured using enzyme activity assays in tissues or cultured cells, often by detecting the formation of acetoacetate or fumarate.
What is the role of succinylacetone in tyrosinemia?
Succinylacetone accumulates when fumarylacetoacetase activity is low and is used as a diagnostic marker for tyrosinemia type I.
Can fumarylacetoacetase deficiency be diagnosed prenatally?
Yes, enzyme activity can be assayed in chorionic villus cells for prenatal diagnosis and carrier detection.
What is self-induced correction in tyrosinemia?
Some patients show spontaneous correction of the FAH defect in a subset of hepatocytes, possibly through genetic reversion or selective advantage.
What CRISPR models are available for studying fumarylacetoacetase activity?
CRISPR knockout, point-mutation knock-in, tagged knock-in and overexpression models can be generated in hepatocyte cell lines or iPSCs to study FAH function.
How does FAH deficiency lead to liver cancer?
Accumulated metabolites like succinylacetone are toxic and carcinogenic, promoting hepatocellular carcinoma in tyrosinemia patients.
Where can I get custom cell models for fumarylacetoacetase research?
EDITGENE provides custom CRISPR knockout, knock-in, overexpression and screening services for FAH and related genes.
Conclusion
Fumarylacetoacetase activity (GO:0004334) is a critical enzymatic function in tyrosine catabolism, and its deficiency causes hereditary tyrosinemia type I. Understanding its mechanism, regulation and disease associations is essential for diagnosis and therapy. CRISPR-based cell models offer powerful tools to study FAH mutations and develop treatments.
References
- 1. Huch M et al.. 2013. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration.. Nature 494(7436):247-50 PMID: 23354049
- 2. Li B et al.. 2026. IL-22 supports long-term expansion of mouse and human hepatocytes.. J Hepatol 84(6):1131-1148 PMID: 41643903
- 3. Huang P et al.. 2014. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes.. Cell Stem Cell 14(3):370-84 PMID: 24582927
- 4. McCormack MJ et al.. 1992. Fumarylacetoacetase activity in cultured and non-cultured chorionic villus cells, and assay in two high-risk pregnancies.. Prenat Diagn 12(10):807-13 PMID: 1475249
- 5. Kvittingen EA et al.. 1985. Concentrations of succinylacetone after homogentisate and tyrosine loading in healthy individuals with low fumarylacetoacetase activity.. Clin Chim Acta 152(3):271-9 PMID: 4064334
- 6. Kvittingen EA et al.. 1986. The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase.. Scand J Clin Lab Invest Suppl 184:35-40 PMID: 3473612
- 8. Kvittingen EA et al.. 1993. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.. J Clin Invest 91(4):1816-21 PMID: 8473520
